For two decades, Xolair was known as an asthma drug. Now it is quietly becoming one of the most consequential medicines in food allergy.
Omalizumab, sold as Xolair by Roche's Genentech division and Novartis, first won FDA approval in 2003 for allergic asthma. The agency expanded that label in February 2024, clearing it for children as young as 1 year old to reduce allergic reactions including anaphylaxis from accidental food exposure. What followed was a cascade of clinical data that is reshaping how doctors think about treating the roughly 5.5 million American children living with food allergies.
The head-to-head evidence comes from Stage 2 of the OUtMATCH trial, a three-stage Phase 3 study sponsored by the NIH and run at Stanford, Johns Hopkins, and other academic centers. In that stage, 117 patients who had already completed initial Xolair treatment were randomized to either continue Xolair with multi-allergen oral immunotherapy (OIT) or to Xolair with placebo OIT. After 16 weeks of treatment, 36 percent of the Xolair monotherapy group could tolerate at least 2,000 milligrams of peanut protein and two other allergens, compared to 19 percent on OIT. The odds ratio was 2.6, a statistically meaningful difference.
The safety picture was not close. Thirty point five percent of OIT patients experienced serious adverse events. Zero Xolair patients did. Twenty-two percent of the OIT group quit the study because of side effects. No Xolair patients did. Epinephrine use for allergic reactions was 37.3 percent in the OIT group and 6.9 percent in the Xolair group.
"These are the first head-to-head data we have had between these two approaches, and the results favor omalizumab," said Dr. Robert Wood, director of the Eudowood Division of Allergy Immunology and Rheumatology at Johns Hopkins Children's Center and a co-author of the study.
The data add context to what researchers described as a pivotal shift in February 2024, when the FDA approved Xolair for food allergy reduction based on earlier OUtMATCH results. In that initial analysis, 68 percent of Xolair patients could tolerate at least 600 milligrams of peanut protein without moderate or severe symptoms, compared to under 7 percent on placebo. The p-value was less than 0.0001, according to the New England Journal of Medicine.
What makes Xolair different from OIT is not that it teaches the immune system to tolerate allergens the way a vaccine does. It works upstream, binding to immunoglobulin E (IgE) in the bloodstream and preventing IgE from arming mast cells and basophils, the immune cells that trigger allergic reactions when they encounter a problem food. Patients still have to avoid their allergens and carry epinephrine. Xolair is not a cure. It is a buffer.
"That buffer is the whole point," said Dr. R. Sharon Chinthrajah, associate professor of medicine at Stanford School of Medicine and co-lead of the OUtMATCH study. "Families tell us they live in a constant state of vigilance. Xolair does not eliminate the allergy. What it does is give patients and parents a margin of safety they did not have before."
The OUtMATCH data raise a question that will take years to answer: does Xolair actually modify the underlying allergy, or does it simply suppress symptoms while treatment is active? The durability data from Stage 3 offer a preliminary and ambiguous answer. After stopping Xolair and entering dietary consumption challenges, approximately 67 percent of children who completed OIT were still eating their allergens a year later. For Xolair patients, that number was 63 percent. The difference was not statistically significant, meaning researchers cannot yet say whether either approach produces lasting tolerance once treatment stops.
The answer matters enormously for how Xolair will be used and priced. If it works only while patients receive injections every two to four weeks, the annual cost of roughly $35,000 to $60,000 becomes a permanent line item in a family's medical budget. If it can be stopped after some period with sustained tolerance, the economics change. Current evidence suggests the latter may be possible for milk, egg, and wheat, where post-treatment success rates ran between 61 and 70 percent. Peanuts and tree nuts were harder: 38 to 56 percent.
The competitive picture is about to get simpler in an unexpected way. Palforzia, the only other FDA-approved food allergy treatment, will be discontinued on July 31, 2026 by Stallergenes Greer, which acquired the peanut powder therapy from Nestlé in September 2023. The company said the decision was not related to safety or efficacy. Palforzia required daily capsules, frequent in-office up-dosing visits, and still caused allergic reactions early in treatment. The complexity was a barrier; discontinuation will leave OIT as a niche option and Xolair as the primary pharmacological choice.
There are limits worth naming. Xolair carries a black box warning for anaphylaxis, the very reaction it is meant to reduce. It does not work for everyone. The drug is expensive. Insurance coverage varies. And the population studied in OUtMATCH, while diverse, was selected for IgE-mediated food allergies, a specific and well-defined subtype. Patients whose allergies work differently will not necessarily see the same results.
The more immediate question is not whether Xolair is a perfect drug. It is whether it is a better option than what existed before. For a condition that has historically been managed by avoidance, epinephrine, and anxiety, the answer increasingly looks like yes.
More data are coming. A multi-site follow-on study is enrolling, and longer-term durability results from OUtMATCH will be presented at upcoming medical meetings. The biology is complex, the timelines are long, and the families waiting are not interested in caveats. But the safety signal is too large to dismiss, and it is strong enough that the field is paying attention.
† Add attribution (e.g., 'according to [source]') or a footnote: '† Source-reported; not independently verified.'
